EUR 50m investment in Kundl plant extension emphasizes commitment to serve more patients with critical antibiotics, produced entirely in Europe Additional manufacturing area of 3,000m 2 means Kundl ...

(Reuters) -Sandoz, the generic drugs business that will be spun off its parent Novartis, will boost investment in its European antibiotics production network by 50 million euros ($50 million) on ...

While much of the pharma industry has shifted its focus away from antibiotics, Novartis' Sandoz unit is doing just the opposite and is charting next steps in a multi-year manufacturing upgrade in ...

Add Yahoo as a preferred source to see more of our stories on Google. FILE PHOTO: The logo of Swiss drugmaker Novartis is pictured at the French company's headquarters in Rueil-Malmaison ZURICH ...

Sandoz, a Novartis division, has signed an agreement to acquire GSK’s cephalosporin antibiotics business. The company said the move is aimed at reinforcing its leading global position in antibiotics.

Investment of EUR 175 million reaffirms Sandoz commitment to long-term leadership in off-patent medicines New penicillin production process will significantly improve ecological footprint and help ...

Sandoz has struck a deal with the Austrian government to invest more than $175 million in its site in Kundl, Austria, Europe’s last large-scale antibiotics plant. Under the plan, which requires formal ...